[1]
|
Abedon ST, Kuhl SJ, Blasdel BG, et al. (2011) Phage treatment of human infections. Bacteriophage 1: 66–85. doi: 10.4161/bact.1.2.15845
|
[2]
|
Abedon ST (2017) Bacteriophage clinical use as antibactertial "drugs": utility, precedent. Microbiol Spectr.
|
[3]
|
Abedon ST (2015) Ecology of anti-biofilm agents I. antibiotics versus bacteriophages. Pharmaceuticals 8: 525–558.
|
[4]
|
Abedon ST (2009) Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog Dis 6: 807–815. doi: 10.1089/fpd.2008.0242
|
[5]
|
Meyer CJ, Deglon DA (2011) Particle collision modeling-a review. Miner Eng 24: 719–730. doi: 10.1016/j.mineng.2011.03.015
|
[6]
|
Bigwood T, Hudson JA, Billington C (2009) Influence of host and bacteriophage concentrations on the inactivation of food-borne pathogenic bacteria by two phages. FEMS Microbiol Lett 291: 59–64. doi: 10.1111/j.1574-6968.2008.01435.x
|
[7]
|
Abedon ST (2014) Bacteriophages as drugs: the pharmacology of phage therapy, In: Borysowski J, Miedzybrodzki R, Górski A, Editors, Phage Therapy: Current Research and Applications, Norfolk, UK: Caister Academic Press, 69–100.
|
[8]
|
Abedon ST (2017) Phage "delay" towards enhancing bacterial escape from biofilms: a more comprehensive way of viewing resistance to bacteriophages. AIMS Microbiol 3: 186–226. doi: 10.3934/microbiol.2017.2.186
|
[9]
|
Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharm Biotechnol 11: 28–47. doi: 10.2174/138920110790725410
|
[10]
|
Górski A, Weber-Dąbrowska B (2005) The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci 62: 511–519. doi: 10.1007/s00018-004-4403-6
|
[11]
|
Payne RJH, Phil D, Jansen VAA (2000) Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther 68: 225–230. doi: 10.1067/mcp.2000.109520
|
[12]
|
Payne RJH, Jansen VAA (2001) Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 208: 37–48. doi: 10.1006/jtbi.2000.2198
|
[13]
|
Payne RJH, Jansen VAA (2003) Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet 42: 315–325. doi: 10.2165/00003088-200342040-00002
|
[14]
|
Levin BR, Bull JJ (2004) Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2: 166–173. doi: 10.1038/nrmicro822
|
[15]
|
Abedon S (2011) Phage therapy pharmacology: calculating phage dosing. Adv Appl Microbiol 77: 1–40. doi: 10.1016/B978-0-12-387044-5.00001-7
|
[16]
|
Worley-Morse TO, Gunsch CK (2015) Modeling phage induced bacterial disinfection rates and the resulting design implications. Water Res 68: 627–636. doi: 10.1016/j.watres.2014.10.025
|
[17]
|
Abedon ST (2015) Ecology of anti-biofilm agents II. bacteriophage exploitation and biocontrol of biofilm bacteria. Pharmaceuticals 8: 559–589.
|
[18]
|
Hagens S, Loessner MJ (2010) Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr Pharm Biotechnol 11: 58–68. doi: 10.2174/138920110790725429
|
[19]
|
Rhoads DD, Wolcott RD, Kuskowski MA, et al. (2009) Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18: 237–244. doi: 10.12968/jowc.2009.18.6.42801
|
[20]
|
Wright A, Hawkins CH, Anggård EE, et al. (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryng 34: 349–357. doi: 10.1111/j.1749-4486.2009.01973.x
|
[21]
|
Miedzybrodzki R, Borysowski J, Weber-Dąbrowska B, et al. (2012) Clinical aspects of phage therapy. Adv Virus Res 83: 73–121. doi: 10.1016/B978-0-12-394438-2.00003-7
|
[22]
|
Sarker SA, McCallin S, Barretto C, et al. (2012) Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434: 222–232. doi: 10.1016/j.virol.2012.09.002
|
[23]
|
Rose T, Verbeken G, Vos DD, et al. (2014) Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 4: 66–73.
|
[24]
|
Fish R, Kutter E, Wheat G, et al. (2016) Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care 25 Suppl 7: S27–S33.
|
[25]
|
Sarker SA, Sultana S, Reuteler G, et al. (2016) Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4: 124–137. doi: 10.1016/j.ebiom.2015.12.023
|
[26]
|
Speck P, Smithyman A (2016) Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett 363.
|
[27]
|
Sarhan WA, Azzazy HM (2015) Phage approved in food, why not as a therapeutic? Expert Rev Anti Infect Ther 13: 91–101. doi: 10.1586/14787210.2015.990383
|
[28]
|
Hyman P, Abedon ST (2010) Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70: 217–248. doi: 10.1016/S0065-2164(10)70007-1
|
[29]
|
Mirzaei MK, Nilsson AS (2015) Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS One 10: e0118557. doi: 10.1371/journal.pone.0118557
|
[30]
|
Abedon ST (2008) Phage, bacteria, and food. Appendix: Rate of adsorption is function of phage density, In: Abedon ST, Editor, Bacteriophage Ecology, Cambridge, UK: Cambridge University Press, 321–324.
|
[31]
|
Guenther S, Loessner MJ (2011) Bacteriophage biocontrol of Listeria monocytogenes on soft ripened white mold and red-smear cheeses. Bacteriophage 1: 94–100. doi: 10.4161/bact.1.2.15662
|
[32]
|
Abedon ST (2015) Bacteriophage secondary infection. Virol Sin 30: 3–10. doi: 10.1007/s12250-014-3547-2
|
[33]
|
Abedon ST (2012) Spatial vulnerability: bacterial arrangements, microcolonies, and biofilms as responses to low rather than high phage densities. Viruses 4: 663–687. doi: 10.3390/v4050663
|
[34]
|
Stent GS (1963) Molecular Biology of Bacterial Viruses, San Francisco, CA: WH Freeman and Co.
|
[35]
|
Abedon ST (2016) Phage therapy dosing: The problem(s) with multiplicity of infection (MOI). Bacteriophage 6: e1220348. doi: 10.1080/21597081.2016.1220348
|
[36]
|
Dulbecco R (1949) Appendix: On the reliability of the Poisson distribution as a distribution of the number of phage particles infecting individual bacteria in a population. Genetics 34: 122–125.
|
[37]
|
Abedon ST (2017) Information phage therapy research should report. Pharmaceuticals (Basel) 10: 43. doi: 10.3390/ph10020043
|
[38]
|
Bryan D, El-Shibiny A, Hobbs Z, et al. (2016) Bacteriophage T4 infection of stationary phase E. coli: life after log from a phage perspective. Front Microbiol 7: 1391.
|
[39]
|
Doolittle MM, Cooney JJ, Caldwell DE (1996) Tracing the interaction of bacteriophage with bacterial biofilms using fluorescent and chromogenic probes. J Indust Microbiol 16: 331–341. doi: 10.1007/BF01570111
|
[40]
|
Sutherland IW, Hughes KA, Skillman LC, et al. (2004) The interaction of phage and biofilms. FEMS Microbiol Lett 232: 1–6. doi: 10.1016/S0378-1097(04)00041-2
|
[41]
|
Filippini M, Buesing N, Bettarel Y, et al. (2006) Infection paradox: high abundance but low impact of freshwater benthic viruses. Appl Environ Microbiol 72: 4893–4898. doi: 10.1128/AEM.00319-06
|
[42]
|
Azeredo J, Sutherland IW (2008) The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 9: 261–266. doi: 10.2174/138920108785161604
|
[43]
|
Bull JJ, Vegge CS, Schmerer M, et al. (2014) Phenotypic resistance and the dynamics of bacterial escape from phage control. PLoS One 9: e94690. doi: 10.1371/journal.pone.0094690
|
[44]
|
Abedon ST (2011) Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques, Hauppauge, New York: Nova Science Publishers.
|
[45]
|
Bull JJ, Regoes RR (2006) Pharmacodynamics of non-replicating viruses, bacteriocins and lysins. Proc R Soc Lond B Biol Sci 273: 2703–2712. doi: 10.1098/rspb.2006.3640
|
[46]
|
Goodridge LD (2010) Designing phage therapeutics. Curr Pharm Biotechnol 11: 15–27. doi: 10.2174/138920110790725348
|
[47]
|
Olszowska-Zaremba N, Borysowski J, Dabrowska J, et al. (2012) Phage translocation, safety, and immunomodulation, In: Hyman P, Abedon ST, Editors, Bacteriophages in Health and Disease, Wallingford, UK: CABI Press, 168–184.
|
[48]
|
Curtright AJ, Abedon ST (2011) Phage therapy: emergent property pharmacology. J Bioanalyt Biomed S3: 010.
|
[49]
|
Abedon ST (2014) Phage therapy: eco-physiological pharmacology. Scientifica 2014: 581639.
|
[50]
|
Stewart PS, Franklin MJ (2008) Physiological heterogeneity in biofilms. Nat Rev Microbiol 6: 199–210. doi: 10.1038/nrmicro1838
|
[51]
|
Wang IN, Dykhuizen DE, Slobodkin LB (1996) The evolution of phage lysis timing. Evol Ecol 10: 545–558. doi: 10.1007/BF01237884
|
[52]
|
Abedon ST, Herschler TD, Stopar D (2001) Bacteriophage latent-period evolution as a response to resource availability. Appl Environ Microbiol 67: 4233–4241. doi: 10.1128/AEM.67.9.4233-4241.2001
|
[53]
|
Niu YD, Stanford K, McAllister TA, et al. (2012) Role of phages in control of bacterial pathogens in food, In: Hyman P, Abedon ST, Editors, Bacteriophages in Health and Disease, Wallingford, UK: CABI Press, 240–255.
|
[54]
|
Bai J, Kim YT, Ryu S, et al. (2016) Biocontrol and rapid detection of food-borne pathogens using bacteriophages and endolysins. Front Microbiol 7: 474.
|
[55]
|
Gill JJ, Young R (2011) Therapeutic applications of phage biology: history, practice and recommendations, In: Miller AA, Miller PF, Editors, Emerging Trends in Antibacterial Discovery: Answering the Call to Arms, Norfolk,UK: Caister Academic Press, 367–410.
|
[56]
|
Hudson J, Billington C, Premaratne A, et al. (2016) Inactivation of Escherichia coli O157:H7 using ultraviolet light-treated bacteriophages. Food Sci Technol Int 22: 3–9.
|
[57]
|
Young VB (2017) The role of the microbiome in human health and disease: an introduction for clinicians. Brit Med J 356: j831.
|
[58]
|
Autenrieth IB (2017) The microbiome in health and disease: a new role of microbes in molecular medicine. J Mol Med 95: 1–3.
|
[59]
|
McCarville JL, Caminero A, Verdu EF (2016) Novel perspectives on therapeutic modulation of the gut microbiota. Therap Adv Gastroenterol 9: 580–593. doi: 10.1177/1756283X16637819
|
[60]
|
Bjarnsholt T (2013) The role of bacterial biofilms in chronic infections. Apmis 121: 1–51.
|
[61]
|
Carlson K (2005) Working with bacteriophages: common techniques and methodological approaches, In: Kutter E, Sulakvelidze A, Editors, Bacteriophages: Biology and Application, Boca Raton, Florida: CRC Press, 437–494.
|
[62]
|
Abedon ST, Expected efficacy: applying killing titer estimations to phage therapy experiments, 2017. Available from: http://killingtiter.phage-therapy.org.
|
[63]
|
Abedon ST, Killing titer calculator, 2017. Available from: http://killingtiter.phage-therapy.org/calculator.html.
|